VYNT 0.21 Stock Price Vyant Bio, Inc.
Range: | 0.141-1.58 | Vol Avg: | 17863 | Last Div: | 0 | Changes: | 0.26 |
Beta: | 0.56 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Thu Apr 01 2021 | Empoloyees: | 4 |
CUSIP: | 92942V109 | CIK: | 0001349929 | ISIN: | US92942V2088 | Country: | US |
CEO: | Mr. Andrew D.C. LaFrence CPA | Website: | https://www.vyantbio.com |
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.